Skromne-Kadlubik G, Hidalgo RR

Language: Spanish
References: 6
Page: 105-106
PDF size: 94.09 Kb.

ABSTRACT

We labell with radionuclides the rituximab and probed in experimental animals with good results. After this we inyected in ten patients with refractary inmune thrombocytopenic purpura (ITP) (2 of them with Evans syndrome). All the patients lowell his CD 20 nivels in blood and have improved his illness without splenectomy in one year of clinical and laboratorial follow-up. Because his simplicity (nor invading procedures), non harmless, encorageous results and low cost we propose the radiorituximab for the treatment of ITP and Evans syndome (with more casuistic of course).

REFERENCES

1. Cines DB, et al. Inmune thrombocytopenia purpura. N Engl J Med 2002; 346: 995.

2. Stasi R, et al. Response to rituximab in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002; 99: 3872.

3. Skromne-Kadlubik G, Hidalgo-Rico R. Preparación de anticuerpos monoclonales. Com Médica 2001; II (6).

4. Tender TF, Engel P. A regulador of cell-cycle progresión. Inmunol Today 1994; 15: 450-4.

5. Sobrevilla P, Rivas S. Anticuerpos monoclonales. Cancerología 2007; 2: 149-58.

6. Boyle J, Ester J, Engert A. Clinical use of anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-35.